Brief: Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA
09/04/2025 11:38
April 9 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: TQB3019 (BTK PROTAC) APPROVED FOR CLINICAL TRIAL BY NMPA Further company coverage: 1177.HK ((Reuter.Briefs@thomsonreuters.com))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up